18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of novel DNA methyltransferase 3A inhibitors via structure-based virtual screening and biological assays.
University of Science and Technology of China
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.
Chinese Academy of Sciences
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A.
University of California
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.
Shandong University
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
University of Palermo
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Southern Medical University
A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A.
University of California
Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.
M. V. Lomonosov Moscow State University
Identification of novel quinazoline derivatives as potent antiplasmodial agents.
University of Lille
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
National University of Singapore
Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
Cnrs-Pierre Fabre Usr3388
